Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 4:15:1594591.
doi: 10.3389/fonc.2025.1594591. eCollection 2025.

Dynamic nomogram for predicting the overall survival and cancer-specific survival of patients with gastrointestinal neuroendocrine tumor: a SEER-based retrospective cohort study and external validation

Affiliations

Dynamic nomogram for predicting the overall survival and cancer-specific survival of patients with gastrointestinal neuroendocrine tumor: a SEER-based retrospective cohort study and external validation

Yipu Wang et al. Front Oncol. .

Abstract

Background: Gastrointestinal neuroendocrine tumor (GI-net) is a rare heterogeneous tumor, and there is a lack of models to predict its prognosis. Our study aims to develop and validate two new nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) of GI-net patients and investigate their application value.

Methods: SEER*Stat 8.4.4 software was used to download clinicopathological information of GI-net patients between 2010 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. These patients were randomly divided into a training group (n=3007) and an internal-validation group (n=1289) at a 7:3 ratio. Patients from the Fourth Hospital of Hebei Medical University were enrolled in this study to form the external-validation group (n=86). Univariate and multivariate Cox analyses were performed to explore the independent prognostic factors and establish two nomograms. The concordance index (C-index), area under the time-dependent receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA) were used to evaluate the nomograms. X-tile was used to divide GI-net patients into high-, medium-, and low-risk groups. Kaplan-Meier (KM) curves and log-rank tests were used to compare survival differences among the three groups.

Results: Seven variables (age, site, size, grade, M stage, surgery, and chemotherapy) were selected to establish the nomogram for OS, and 6 variables (age, size, grade, M stage, surgery, and chemotherapy) were selected for CSS. The C indices (0.785, 0.813, and 0.936 in the training, internal-validation, and external-validation groups for OS; 0.888, 0.893, and 0.930 for CSS, respectively) and AUCs (≥0.7) indicated that the nomograms had satisfactory discriminative ability. Calibration curve analysis and DCA revealed that the nomogram had a satisfactory ability to predict OS and CSS. KM curves indicated that each of the two nomograms clearly differentiated the high-, medium-, and low-risk groups. In addition, two online risk calculators were developed to predict the OS and CSS of these patients visually.

Conclusions: Our nomograms may play an important role in predicting 3- and 5-year OS and CSS for GI-net patients. Risk stratification systems and online risk calculators can be utilized in clinical practice to help doctors create personalized treatment plans.

Keywords: cancer-specific survival (CSS); gastrointestinal neuroendocrine tumor (GI-net); nomogram; overall survival (OS); surveillance epidemiology and end results (SEER) database.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The flowchart of patients inclusion among the SEER database. The flow diagram of selection of patients with GI-net in this study.
Figure 2
Figure 2
The optimal cut-off value of age and size calculated by X-tile. The age and size data were presented in a triangular grid pattern. Each pixel highlight represented the log-rank teat value [(A) age of OS, (C) size of OS, (E) age of CSS, (G) size of CSS], the distribution of the number of patients is shown in the histogram (B) age of OS, [(D) size of OS, (F) age of CSS, (H) size of CSS]. OS, overall survival; CSS, cancer-specific survival.
Figure 3
Figure 3
Nomograms for predicting 3- and 5-year OS and CSS of GI-net patients. (A) nomogram to predict 3-, and 5-year OS for GI-net patients; (B) nomogram to predict 3-, and 5-year CSS for GI-net patients. OS, overall survival; CSS, cancer-specific survival.
Figure 4
Figure 4
Time-dependent ROC curves of nomograms. (A) Time-dependent ROC curves of the OS nomogram showed that the AUCs in the training group were 0.7799,and 0.7993 for predicting 3-year and 5-year OS, respectively. (B) Time-dependent ROC curves of the OS nomogram showed that the AUCs in the internal-validation group were 0.8542, and 0.8493 for predicting 3-year and 5-year OS, respectively. (C) Time-dependent ROC curves of the OS nomogram showed that the AUCs in the external-validation group were 0.9812, and 0.9901 for predicting 3-year and 5-year OS, respectively. (D) Time-dependent ROC curves of the CSS nomogram showed that the AUCs in the training group were 0.8730, and 0.9051 for predicting 3-year and 5-year CSS, respectively. (E) Time-dependent ROC curves of the CSS nomogram showed that the AUCs in the internal-validation group were 0.9100 and 0.9098 for predicting 3-year and 5-year CSS, respectively. (F) Time-dependent ROC curves of the CSS nomogram showed that the AUCs in the external-validation group were 0.9812 and 0.9911 for predicting 3-year and 5-year CSS, respectively. AUC, area under the time‐dependent receiver operating characteristic curves; OS, overall survival; CSS, cancer-specific survival.
Figure 5
Figure 5
Calibration curves of nomograms. (A–C) Calibration curves of 3-year and 5-year OS for GI-net patients in training, internal-validation, and external-validation groups. (D–F) Calibration curves of 3-year and 5-year CSS for GI-net patients in training, internal-validation, and external-validation groups. GI-net, gastrointestinal neuroendocrine tumor; OS, overall survival; CSS, cancer-specific survival.
Figure 6
Figure 6
Decision curve analysis (DCA) of nomograms. (A–C) DCA of 3-year and 5-year OS for GI-net patients in training, internal-validation, and external-validation groups. (D–F) DCA of 3-year and 5-year CSS for GI-net patients in training, internal-validation, and external-validation groups. GI-net, gastrointestinal neuroendocrine tumor; OS, overall survival; CSS, cancer-specific survival.
Figure 7
Figure 7
The optimal cut-off value of nomograms score calculated by X-tile. The nomogram score data were presented in a triangular grid pattern. Each pixel highlight represented the log-rank teat value [(A) nomogram score of OS, (C) nomogram score of CSS], the distribution of the number of patients is shown in the histogram [(B) nomogram score of OS, (D) nomogram score of CSS]. OS, overall survival; CSS, cancer-specific survival.
Figure 8
Figure 8
Kaplan–Meier survival analyses for GI-net patients according to the risk stratification. Survival curves showed the OS [(A) and CSS (D) of the low-risk (1: red),medium-risk (2: green) and high-risk (3: blue) groups in the training group, the OS (B) and CSS (E) in the internal-validation group, and the OS (C)] and CSS (F) in the external-validation group. GI-net, gastrointestinal neuroendocrine tumor; OS, overall survival; CSS, cancer-specific survival.

Similar articles

References

    1. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: A review of neuroendocrine tumors and carcinomas. Neoplasia (New York NY). (2017) 19:991–1002. doi: 10.1016/j.neo.2017.09.002 - DOI - PMC - PubMed
    1. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Cancer Network: JNCCN. (2018) 16:693–702. doi: 10.6004/jnccn.2018.0056 - DOI - PubMed
    1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin oncology: Off J Am Soc Clin Oncology. (2008) 26:3063–72. doi: 10.1200/JCO.2007.15.4377 - DOI - PubMed
    1. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocrine pathology. (2022) 33:115–54. doi: 10.1007/s12022-022-09708-2 - DOI - PubMed
    1. Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumors: a systematic review of the literature. Endocrine-related cancer. (2014) 21:R153–63. doi: 10.1530/ERC-13-0125 - DOI - PubMed

LinkOut - more resources